Interim Report, January-March 2015 January-March 2015

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Interim Report, January-March 2015

January-March 2015[1] · Net sales reached SEK 4,583 million (3,365), corresponding to an increase of 36%, 24% at constant exchange rates compared to the previous year. · EBITDA, excluding non-recurring items, was SEK 1,403 million (1,010), corresponding to an increase of 39%, 26% at constant exchange rates and yielding a 30.6% margin (30.0). · Non-recurring effects had a SEK 218 million negative impact on earnings before tax. · Profit after tax amounted to SEK 226 million (260). · Earnings per share reached SEK 0.62 (0.83)[2]. Excluding non-recurring effects, earnings per share totaled SEK 0.59 (0.83). · Cash earnings per share amounted to SEK 0.74 (1.90)[2]. Excluding non -recurring effects cash earnings per share totaled SEK 1.94 (1.90). +----------------------------------------------------------------------------+ |1)     For information about non-recurring effects, see page 62)      | |Recalculation of comparative figures to consider the bonus issue elements in| |the 2014 new share issue. | +----------------------------------------------------------------------------+ | | +----------------------------------------------------------------------------+ CEO statement Q1 2015 marked another quarter of transformational growth. Sales came in at SEK 4,583 million, 36% higher compared to last year (+24% CER). While weaker than previous quarter due to seasonality, sales were ahead of our internal plans. The integration of Rottapharm continues to proceed according to plan and the benefits are flowing through to the bottom line. I am very pleased that our operating expenses are more than SEK 200 million lower in Q1 2015 versus Q1 last year on a pro forma basis at constant exchange rates. This means that we continue to be very confident to achieve our synergy commitment of SEK 900 million of run-rate synergies in 2016 from the deal. In fact, we are relentlessly working to fully exploit the best of Meda and Rottapharm. This again proves that turning Meda into a leader in European specialty pharma through the acquisition of Rottapharm was the right move at the right time. Identifying, executing and integrating acquisitions is a core skill for Meda and Q1 2015 reinforced my conviction that M&A is at the very heart of Meda’s strategy going forward. Sales in the Rx product area (prescription drugs) reached SEK 2,820 million in Q1, corresponding to 14% growth (+3% CER). Some of our prioritized products continue to deliver. In Respiratory, Dymista prescriptions in the US continue to grow at around 30% although wholesalers reduced their inventory levels in the quarter. This was complemented by good growth in Western Europe (40% in constant exchange rates). EpiPen was up 20% (+7% CER). Also, since end of February, Aerospan prescriptions have more than doubled. Furthermore, in Dermatology I am very pleased to note that we are back at normalized supply for Elidel. The product rebounded - increase of 23% (+10% CER) thanks to good performance in Emerging Markets - which in light of the uncertainty of last year proves the strength of this franchise and end-customer loyalty. The Cx/OTC product area (non-prescription products) reached SEK 1,650 million in sales in Q1, corresponding to a 93% increase (+78 % CER). New product additions from the Rottapharm business performed well. Dona, Meda’s largest product, increased by 42% (+21% CER) compared last year driven by strong performance in Emerging Markets. Also, Legalon with an 18% increase (+8% CER) showed good growth. CB12 sales were weaker compared to previous quarters as anticipated as marketing activity was muted ahead of the new product campaign launch in April. At the end of the day, sales need to flow to the EBITDA and cash flow lines. And I am pleased that they did. EBITDA was taken to a new level, up 39% (+26% CER). Also, despite accumulation of working capital, free cash flow was up 19%. It is noteworthy that both measures were supported by the gross margin expansion of 1% -point to 62%. We will continue down the path we have set upon – building a bigger, stronger and better Meda. Nothing will distract us from this objective. Our focus for the rest of the year is threefold: to fully exploit the synergy potential from the Rottapharm acquisition, to strengthen our cash flow, and to gear up for further M&A by building pipeline for 2016. We remain committed to the guidance as communicated earlier. Jörg-Thomas Dierks Group President and CEO CER = constant exchange rates The company’s auditors did not review this interim report. Webcasted presentation of the report on May 6 at 10:30 AM. The presentation can be accessed at www.meda.se/sv/investerare, where a recorded version will also be available until the next interim report.For further inquiries, please contact: Paula Treutiger, VP Corporate Communications & Sustainability, paula.treutiger@meda.se, +46 733-666 599. Forward-looking statement This report is not an offer to sell or a solicitation to buy shares in Meda. This report also contains certain forward-looking statements with respect to certain future events and Meda’s potential financial performance. These forward -looking statements can be identified by the fact that they do not relate only to historical or current facts and may sometimes include words such as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”, “forecast”, “believe”, or other words of similar meaning. These forward-looking statements reflect the current expectations on future events of the management at the time such statements are made, but are made subject to a number of risks and uncertainties. In the event such risks or uncertainties materialize, Meda’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research and product development, manufacturing and commercialization, the impact of competitive products, patents, legal challenges, government regulation and approval, Meda’s ability to secure new products for commercialization and/or development, and other risks and uncertainties detailed from time to time in Meda AB’s interim or annual reports, prospectuses, or press releases. Listeners and readers are cautioned that no forward-looking statement is a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. Meda does not intend or undertake to update any such forward-looking statements.  Meda AB discloses the information provided herein pursuant to the Securities Market Act and/or the Financial Instruments Trading Act. This information was submitted for publication on May 6, 2015 at 8:00 AM. Meda AB Pipers väg 2A, Box 906, 170 09 Solna, Sweden, Tel: +46 8-630 19 00, Fax: +46 8 -630 19 50, email: info@meda.se, www.meda.se, Corp. ID: 556427-2812

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 60

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 65

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 124

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts

Updated Category News Views 125

A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 54

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 52

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 0

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 416

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 65

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 98

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading

Top 5 Most Recently Viewed Articles

Navigating Market Trends: The January Barometer Insights

Updated Category News Views 253

The January Barometer: Understanding Market Signals As winter unfolds across the nation, investors find themselves grappling with an important phase in the market cycle. Just as severe weather can disrupt travel and economies, the performance of the stock market in January is a pivotal signal for the year ahead. The January Barometer indicates that the market's momentum...

Continue Reading
Cloudflare Pushes for Enhanced Security in Public Sector Globally

Updated Category News Views 304

Cloudflare Expands Security Efforts in the Public Sector Cloudflare, Inc. (NYSE: NET), a frontrunner in the connectivity cloud landscape, is announcing significant strides in its mission to bolster public sector security across various nations. The company is working diligently towards achieving FedRAMP High authorization in the U.S. and is also pursuing the InfoSec...

Continue Reading
Empowering Digital Creators: The Rise of CreatorFi Solutions

Updated Category News Views 470

Insomnia Labs Launches CreatorFi: A New Frontier for Creators Insomnia Labs has taken a bold step forward in the financial technology space with the introduction of CreatorFi, a platform exclusively designed for digital creators. This innovative service offers stablecoin-based credit solutions which have been built on the robust Avalanche blockchain. Initial funding for...

Continue Reading
Padlock Euro Storage Fund I Expands with SBR WB Limited Purchase

Updated Category News Views 163

Padlock Euro Storage Fund I Completes Strategic Acquisition Padlock Euro Storage Fund I, a recognized investment player, has recently announced its acquisition of SBR WB Limited. This transaction marks a significant step forward for the Trust as it expands its presence in the self-storage property market. Details on the Acquisition The acquisition involved a total...

Continue Reading
Dream's $260M Boost: AI for Sovereign Nations

Updated Category News Views 44

A Nation's Dream of Technological Independence Government control over infrastructure isn't new—roads, grids, you name it. But AI? That's the next giant to conquer. Dream's got its eye on making sure governments don't have to rely on foreign tech firms for their defense systems. A $3 billion valuation just three years in tells you they're onto something big. The...

Continue Reading